Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Spe…
This bill directs the Director of the National Cancer Institute (NCI) to conduct a comprehensive review of stomach (gastric) cancer in the United States, covering incidence, risk factors (including H. pylori), screening availability and effectiveness, endoscopic treatment and surveillance, public and provider awareness, and current federal efforts. The NCI must deliver a report to Congress within 18 months with recommendations on defining high-risk populations, identifying and detecting high-risk individuals, routine screening guidelines, and actions to improve research, prevention, early diagnosis, screening, and treatment.
Scope of federal action: liberals want funded follow-through and implementation; conservatives want evidence-only and protections against unfunded mandates.
Relative to its intended legislative type, this bill provides a clear, specific mandate for agency-conducted reviews and reports on stomach cancer and a DoD study; it names responsible actors, lists detailed review elements, and sets an 18-month reporting deadline.
This bill directs the Director of the National Cancer Institute (NCI) to conduct a comprehensive review of stomach (gastric) cancer in the United States, covering incidence, risk factors (including H. pylori), screening availability and effectiveness, endoscopic treatment and surveillance, public and provider awareness, and current federal efforts.
The NCI must deliver a report to Congress within 18 months with recommendations on defining high-risk populations, identifying and detecting high-risk individuals, routine screening guidelines, and actions to improve research, prevention, early diagnosis, screening, and treatment.
The bill also requires the Secretary of Defense, coordinated with NCI and CDC, to study stomach cancer incidence, risk factors (including service- or deployment-related exposures such as burn pits and contaminated water), disparities, and availability of screening/diagnostic/treatment services for active-duty and former service members; that study must likewise be reported to Congress within 18 months with policy and integration recommendations for military and VA health systems.
Content-wise this is a modest, technical fact-finding bill that fits squarely within federal agency missions (NCI, CDC, DoD) and does not impose spending or regulatory mandates; such bills frequently advance because they produce information useful to policymakers and stakeholders. The inclusion of military exposure language raises the profile and could attract stakeholder pressure that either helps (broad support for veterans' health studies) or complicates (calls to attach benefits/funding) enactment. Absence of funding authorization is typical for report bills but may slow implementation if agencies require additional resources.
Relative to its intended legislative type, this bill provides a clear, specific mandate for agency-conducted reviews and reports on stomach cancer and a DoD study; it names responsible actors, lists detailed review elements, and sets an 18-month reporting deadline. The bill is strong on defining scope and deliverables but omits funding directions, data access/privacy safeguards, and explicit follow-up or implementation mechanisms.
Scope of federal action: liberals want funded follow-through and implementation; conservatives want evidence-only and protections against unfunded mandates.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope of federal action: liberals want funded follow-through and implementation; conservatives want evidence-only and protections against unfunded mandates.
A mainstream liberal would likely view the bill positively as a targeted, evidence-building step to address a cancer that shows racial and ethnic disparities and is relatively under-recognized in the U.S. health agenda.
They would appreciate the focus on H. pylori, high-risk populations, and the inclusion of military and veteran populations who may face unique exposures.
However, they would note the bill stops short of guaranteeing implementation, new resources, or coverage for screening and treatment, and would want follow-up action to translate findings into equitable care access.
A pragmatic centrist would view the bill as a reasonable, low-risk, data-driven step to clarify whether expanded screening or prevention efforts for stomach cancer are warranted, especially in identified high-risk groups and among service members.
They would appreciate that the bill commissions reviews rather than mandating immediate national screening, allowing policy to follow evidence.
At the same time, they would want clarity on costs, timelines, and whether the agencies have capacity to perform the mandated work within 18 months and without new funding.
A mainstream conservative would likely see the bill as a limited, targeted request for study that is modest in scope because it asks federal agencies to review evidence rather than imposing new mandates.
They may welcome the attention to military and veteran health issues and the focus on potential service-related exposures.
Nonetheless, they would be cautious that study findings could be used to justify expanded federal screening programs, regulatory directives, or entitlement-like coverage expansions with fiscal consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise this is a modest, technical fact-finding bill that fits squarely within federal agency missions (NCI, CDC, DoD) and does not impose spending or regulatory mandates; such bills frequently advance because they produce information useful to policymakers and stakeholders. The inclusion of military exposure language raises the profile and could attract stakeholder pressure that either helps (broad support for veterans' health studies) or complicates (calls to attach benefits/funding) enactment. Absence of funding authorization is typical for report bills but may slow implementation if agencies require additional resources.
The bill has not accumulated any surfaced votes yet.
Scope of federal action: liberals want funded follow-through and implementation; conservatives want evidence-only and protections against u…
Content-wise this is a modest, technical fact-finding bill that fits squarely within federal agency missions (NCI, CDC, DoD) and does not i…
Relative to its intended legislative type, this bill provides a clear, specific mandate for agency-conducted reviews and reports on stomach cancer and a DoD study; it names responsible actors, lists detailed review elem…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.